title: [Immunosuppressive agents in kidney transplantation].
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nishi
mesh_terms: D000906:Antibodies / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D000068338:Everolimus; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016030:Kidney Transplantation; D011409:Propylene Glycols / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives; D013601:T-Lymphocytes / Q000276:immunology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000906:Antibodies; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; D016572:Cyclosporine; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D020123:Sirolimus; D016559:Tacrolimus